Seattle Genetics No Longer On Goldman Sachs' Sell List By: Benzinga via Benzinga September 15, 2016 at 09:48 AM EDT Seattle Genetics, Inc. (NASDAQ: SGEN) received a ratings bump from Goldman Sachs to Neutral from Sell after the brokerage revised its ... Read More >> Related Stocks: Bristol-Myers Squibb Merck & Co Seagen Inc